Traumatic Brain Injury - Pipeline Review, H2 2017

Date: July 11, 2017
Pages: 252
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until September 1, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: TFA2C186293EN
Leaflet:

Download PDF Leaflet

Traumatic Brain Injury - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Pipeline Review, H2 2017, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 9, 55 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Traumatic Brain Injury - Overview
Traumatic Brain Injury - Therapeutics Development
Traumatic Brain Injury - Therapeutics Assessment
Traumatic Brain Injury - Companies Involved in Therapeutics Development
Traumatic Brain Injury - Drug Profiles
Traumatic Brain Injury - Dormant Projects
Traumatic Brain Injury - Discontinued Products
Traumatic Brain Injury - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Traumatic Brain Injury, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Traumatic Brain Injury - Pipeline by ALSP Inc, H2 2017
Traumatic Brain Injury - Pipeline by Apollo Endosurgery Inc, H2 2017
Traumatic Brain Injury - Pipeline by Aptinyx Inc, H2 2017
Traumatic Brain Injury - Pipeline by Athersys Inc, H2 2017
Traumatic Brain Injury - Pipeline by Beech Tree Labs Inc, H2 2017
Traumatic Brain Injury - Pipeline by Biogen Inc, H2 2017
Traumatic Brain Injury - Pipeline by Cantex Pharmaceuticals Inc, H2 2017
Traumatic Brain Injury - Pipeline by Cognosci Inc, H2 2017
Traumatic Brain Injury - Pipeline by Eustralis Pharmaceuticals Ltd, H2 2017
Traumatic Brain Injury - Pipeline by Intellect Neurosciences Inc, H2 2017
Traumatic Brain Injury - Pipeline by International Stem Cell Corp, H2 2017
Traumatic Brain Injury - Pipeline by Ischemix Inc, H2 2017
Traumatic Brain Injury - Pipeline by JT Pharmaceuticals Inc, H2 2017
Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals Inc, H2 2017
Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017
Traumatic Brain Injury - Pipeline by MandalMed Inc, H2 2017
Traumatic Brain Injury - Pipeline by Mapreg SAS, H2 2017
Traumatic Brain Injury - Pipeline by Neuralstem Inc, H2 2017
Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Ltd, H2 2017
Traumatic Brain Injury - Pipeline by Neurofx Inc, H2 2017
Traumatic Brain Injury - Pipeline by NeuroNascent Inc, H2 2017
Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H2 2017
Traumatic Brain Injury - Pipeline by New World Laboratories Inc, H2 2017
Traumatic Brain Injury - Pipeline by NoNO Inc, H2 2017
Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H2 2017
Traumatic Brain Injury - Pipeline by Omeros Corp, H2 2017
Traumatic Brain Injury - Pipeline by Oxeia Biopharmaceuticals Inc, H2 2017
Traumatic Brain Injury - Pipeline by Prevacus Inc, H2 2017
Traumatic Brain Injury - Pipeline by QR Pharma Inc, H2 2017
Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017
Traumatic Brain Injury - Pipeline by Rubicon Biotechnology Inc, H2 2017
Traumatic Brain Injury - Pipeline by Sage Therapeutics Inc, H2 2017
Traumatic Brain Injury - Pipeline by SanBio Inc, H2 2017
Traumatic Brain Injury - Pipeline by STATegics Inc, H2 2017
Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2017
Traumatic Brain Injury - Pipeline by SynZyme Technologies LLC, H2 2017
Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H2 2017
Traumatic Brain Injury - Pipeline by vasopharm GmbH, H2 2017
Traumatic Brain Injury - Pipeline by VG Life Sciences Inc, H2 2017
Traumatic Brain Injury - Dormant Projects, H2 2017
Traumatic Brain Injury - Dormant Projects, H2 2017 (Contd..1), H2 2017
Traumatic Brain Injury - Dormant Projects, H2 2017 (Contd..2), H2 2017
Traumatic Brain Injury - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Traumatic Brain Injury, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017
Skip to top


Brain Injury - Pipeline Review, H1 2015 US$ 1,700.00 Jan, 2015 · 43 pages
Reperfusion Injury - Pipeline Review, H2 2014 US$ 1,700.00 Nov, 2014 · 52 pages
Brain Metastasis - Pipeline Review, H2 2015 US$ 1,700.00 Jul, 2015 · 194 pages

Ask Your Question

Traumatic Brain Injury - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: